The MPA treatment market is growing as biologic drugs like rituximab and new options such as avacopan become preferred for their targeted effects and lower relapse rates. Pharma companies are pushing new biologics and precision medicine, but high drug costs and side effects still limit access, especially in lower-income regions. Improved diagnostics and regulatory support are helping expand treatment, and emerging markets are expected to see more access to advanced therapies for this rare autoimmune disease.